3383.4000 -67.50 (-1.96%)
NSE Aug 21, 2025 15:31 PM
Volume: 109.6K
 

3383.40
-1.96%
ICICI Securities Limited
Dr Lal’s Pathlabs’ Q1 volume growth at 2.5% was impacted to some extent due to seasonality. Favourable test mix and traction in Swasthfit improved realisation per patient by 8.5% to INR 789 and aided gross margin expansion of 181bps YoY.
Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr
More from Dr. Lal Pathlabs Ltd.
Recommended